Condition

Ovarian cancer

Clinical trials and treatment information for Ovarian cancer

1.2M
People Affected
200
Active Trials
428K
New Cases/Year
186K
Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

1
Olaparib
78% Effectiveness• 90% Confidence• 50% Safety• 143 trials• 8K participants
HIGH EvidenceGood ValueDose: 300 mg twice daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe

Time to Effect

1-3 months

Duration

2-3 years

Response Rate

70%

Remission Rate

30%

Number Needed to Treat (NNT)

2

Number Needed to Harm (NNH)

15

Common Side Effects:

Nausea: 65%
Fatigue: 55%
Anemia: 45%
Vomiting: 30%
Diarrhea: 25%
Myelodysplastic syndrome/AML: 0.5%

Annual Cost of Care

Drug Cost

$360,000

Monitoring

$6,000

Side Effects

$3,000

Total Annual

$369,000

Cost-Effectiveness

GOOD

QALYs Gained

2.7

ICER

$70,000/QALY

Cost per Remission

$1,230,000

Cost per Responder

$527,143

Treatment Outcomes
Primary Outcomes
Progression-Free Survival (PFS)5.5 months (median in relapsed platinum-sensitive ovarian cancer, BRCAm)
+247% (+13.6 months)
Time to First Subsequent Therapy or Death (TFST)9.3 months (median in relapsed platinum-sensitive ovarian cancer, BRCAm)
+170% (+15.8 months)
Objective Response Rate (ORR)10% (in heavily pre-treated relapsed platinum-resistant ovarian cancer, BRCAm)
+250% (+25 percentage points)
Time to Second Progression or Death (PFS2)15.3 months (median in relapsed platinum-sensitive ovarian cancer, BRCAm)
+139% (+21.2 months)
Secondary Benefits
Overall Survival (OS)44.9 months (median in relapsed platinum-sensitive ovarian cancer, BRCAm)
+15% (+6.8 months)
Health-Related Quality of Life (FACT-O Total Score)100 points (FACT-O total score, range 0-148, higher is better)
+2% (+2 points)
Time to Deterioration in HRQoL (FACT-O)13.9 months (median for placebo in first-line maintenance setting)
+105% (+14.6 months)
Common Side Effects
Nausea
+65%
Fatigue
+55%
Anemia
+45%

Clinical Trial Phases:

Phase 3Phase 4
2
Niraparib
77% Effectiveness• 90% Confidence• 50% Safety• 95 trials• 5K participants
HIGH EvidenceModerate ValueDose: 200-300 mg once daily
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe

Time to Effect

1-3 months

Duration

2-3 years

Response Rate

68%

Remission Rate

25%

Number Needed to Treat (NNT)

4

Number Needed to Harm (NNH)

3

Common Side Effects:

Thrombocytopenia: 35%
Anemia: 25%
Nausea: 55%
Fatigue: 45%
Hypertension: 25%

Annual Cost of Care

Drug Cost

$192,000

Monitoring

$7,000

Side Effects

$4,000

Total Annual

$203,000

Cost-Effectiveness

MODERATE

QALYs Gained

2.6

ICER

$130,000/QALY

Cost per Remission

$812,000

Cost per Responder

$298,529

Treatment Outcomes
Primary Outcomes
Median Progression-Free SurvivalTypical PFS in similar patients without Niraparib: 5.5 months
+281.8% (+15.5 months)
CA-125 LevelsBaseline CA-125 level: 150 U/mL
-50% (-75 U/mL)
Tumor Size Reduction (RECIST)Baseline Sum of Longest Diameters (RECIST): 50 mm
-40% (-20 mm)
Secondary Benefits
Time to First Subsequent Therapy or DeathTypical TFST in similar patients without Niraparib: 8.5 months
+203.5% (+17.3 months)
Quality of Life (FACT-O Total Score)FACT-O total score: 90/160
+8% (+7.2 points)
Time to Second Subsequent Therapy or DeathTypical TSST in similar patients without Niraparib: 15.5 months
+117.4% (+18.2 months)
Common Side Effects
Thrombocytopenia
+35%
Anemia
+25%
Nausea
+55%

Clinical Trial Phases:

Phase 3Phase 4
3
Carboplatin + Paclitaxel
75% Effectiveness• 95% Confidence• 30% Safety• 347 trials• 50K participants
HIGH EvidenceExcellent ValueDose: Carboplatin AUC 5-6 + Paclitaxel 175 mg/m2 IV q3w for 6 cycles
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe

Time to Effect

1-2 months

Duration

4.5-6 months

Response Rate

75%

Remission Rate

40%

Common Side Effects:

Myelosuppression (Neutropenia, Anemia): 70%
Alopecia: 85%
Peripheral Neuropathy: 40%
Nausea/Vomiting: 60%
Fatigue: 75%

Annual Cost of Care

Drug Cost

$5,000

Monitoring

$7,500

Side Effects

$7,500

Total Annual

$20,000

Cost-Effectiveness

EXCELLENT

QALYs Gained

2

Cost per Remission

$50,000

Cost per Responder

$26,667

Treatment Outcomes
Primary Outcomes
CA-125 Level500 U/mL
-80% (-400 U/mL)
Sum of Diameters of Target Lesions (RECIST)10 cm
-50% (-5 cm)
Estimated Ascites Volume5 L (moderate-severe)
-60% (-3 L)
Cancer-Related Pain (NRS 0-10)7/10
-50% (-3.5 points)
Secondary Benefits
Quality of Life (EORTC QLQ-C30 Global Health Status)50/100
+20% (+10 points)
Performance Status (ECOG 0-5)2/5
-50% (-1 point)
Cancer-Related Fatigue (FACIT-F score 0-52)25/52
+15% (+3.75 points)
Common Side Effects
Myelosuppression (Neutropenia, Anemia)
+70%
Alopecia
+85%
Peripheral Neuropathy
+40%

Clinical Trial Phases:

Phase 3Phase 4
4
Bevacizumab
70% Effectiveness• 90% Confidence• 45% Safety• 258 trials• 10K participants
HIGH EvidenceModerate ValueDose: 15 mg/kg IV q3w
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe

Time to Effect

1-3 months

Duration

12-15 months

Response Rate

60%

Remission Rate

20%

Number Needed to Treat (NNT)

8

Number Needed to Harm (NNH)

25

Common Side Effects:

Hypertension: 30%
Proteinuria: 20%
Fatigue: 40%
Nausea/Vomiting: 15%
Gastrointestinal perforation: 3%
Bleeding: 15%

Annual Cost of Care

Drug Cost

$115,000

Monitoring

$8,000

Side Effects

$4,000

Total Annual

$127,000

Cost-Effectiveness

MODERATE

QALYs Gained

2.2

ICER

$120,000/QALY

Cost per Remission

$635,000

Cost per Responder

$211,667

Treatment Outcomes
Primary Outcomes
Median Progression-Free Survival10.0 months (with chemotherapy alone)
+40% (+4.0 months)
Median Overall Survival30.0 months (with chemotherapy alone)
+13.33% (+4.0 months)
Objective Response Rate (RECIST)15% (with chemotherapy alone in recurrent setting)
+100% (+15%)
CA-125 Serum Level800 U/mL (in advanced disease)
-50% (-400 U/mL)
Secondary Benefits
EORTC QLQ-C30 Global Health Status Score50/100 (lower score indicates poorer QoL)
+20% (+10 points)
Ascites Volume4.0 Liters (moderate to severe ascites)
-50% (-2.0 Liters)
Disease Control Rate (ORR + Stable Disease)40% (with chemotherapy alone in recurrent setting)
+62.5% (+25%)
Common Side Effects
Hypertension
+30%
Proteinuria
+20%
Fatigue
+40%

Clinical Trial Phases:

Phase 3Phase 4
5
Liposomal Doxorubicin
60% Effectiveness• 85% Confidence• 32% Safety• 260 trials• 7.5K participants
HIGH EvidenceModerate ValueDose: 50 mg/m2 IV q4w
Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe

Time to Effect

1-2 months

Duration

3-6 months

Response Rate

35%

Remission Rate

8%

Number Needed to Treat (NNT)

7

Number Needed to Harm (NNH)

12

Common Side Effects:

Hand-Foot Syndrome: 45%
Myelosuppression (Neutropenia): 35%
Nausea/Vomiting: 25%
Stomatitis/Mucositis: 25%
Alopecia: 15%

Annual Cost of Care

Drug Cost

$9,000

Monitoring

$7,000

Side Effects

$5,000

Total Annual

$21,000

Cost-Effectiveness

MODERATE

QALYs Gained

0.5

Cost per Remission

$262,500

Cost per Responder

$60,000

Treatment Outcomes
Primary Outcomes
CA-125 Levels500 U/mL
-60% (-300 U/mL)
Tumor Size (Sum of Longest Diameters, RECIST)50 mm
-35% (-17.5 mm)
Ascites Severity Score (0-3 scale)2/3 (moderate ascites)
-50% (-1 point)
Median Progression-Free Survival6.0 months (median with standard platinum-based therapy)
+25% (+1.5 months)
Secondary Benefits
EORTC QLQ-C30 Global Health Status/QoL score45/100 points
+26.6% (+12 points)
FACT-O Fatigue Subscale Score (higher is better)15/44 points
+20% (+3 points)
Common Side Effects
Hand-Foot Syndrome
+45%
Myelosuppression (Neutropenia)
+35%
Nausea/Vomiting
+25%

Clinical Trial Phases:

Phase 3Phase 4